Inibidores do SGLT2 no manejo da insuficiência cardíaca em pacientes com FA: uma revisão integrativa
DOI:
https://doi.org/10.34119/bjhrv8n4-044Keywords:
insuficiência cardíaca, inibidores do SGLT2, remodelamento miocárdico, fibrilação atrialAbstract
O complexo diagnóstico da Insuficiência Cardíaca (IC) abarca sintomas dispneicos, fadiga e outros sinais de sobrecarga de volume oriundos de processos, como a própria falha da bomba cardíaca até injúrias renais. Desse modo, caracteriza-se como uma síndrome de difícil manejo terapêutico. Complementarmente, não é incomum a IC estar associada à Fibrilação Atrial (FA), o que pode ainda piorar o prognóstico. Para a melhora do processo saúde-doença desses pacientes, novos fármacos são constantemente estudados no tratamento concomitante da IC e da FA. Este trabalho visou analisar os impactos do uso dos inibidores do SGLT2 no manejo da insuficiência cardíaca em pacientes com FA. Para isso, foi efetuada uma revisão literária integrativa por meio das bases de dados PubMed e SciElo. Os critérios de inclusão envolveram trabalhos escritos na língua inglesa, completos e publicados nos últimos 5 anos. Como critérios de exclusão, estudos incompletos, publicados em idiomas além do inglês, apresentações de pôsteres, relatos de casos e editoriais. Após, os artigos foram sistematizados no diagrama de fluxo Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) e tabulados. Por fim, obteve-se como resultados que os inibidores de SGLT2 são uma classe de medicamentos promissora para o manejo de insuficiência cardíaca, com efeitos variáveis sobre a fibrilação atrial, especialmente em populações específicas, como pacientes com diabetes tipo 2 e insuficiência cardíaca com fração de ejeção reduzida. No entanto, mais estudos são necessários para determinar os mecanismos exatos que conferem esses benefícios, bem como a eficácia de diferentes glifozinas.
References
ALDAFAS, R. et al. (2024). Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis. Age Ageing, 53(1), afad254. https://doi.org/10.1093/ageing/afad254
Available at: https://www.nyheartassociation.org/classification. Acesso em 25 dezembro de 2024.
BOZKURT, B. et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. European Journal of Heart Failure, v. 23, n. 3, p. 352-380, 2021. DOI: https://doi.org/10.1002/ejhf.2115.
evidence and guidelines. Pharmacology & Therapeutics, v. 238, p. 108185, out. 2022. DOI:
FERNANDES, G. C. et al. (2021). Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials. Heart Rhythm, 18(7), 1098-1105. https://doi.org/10.1016/j.hrthm.2021.03.028
GOPINATHANNAIR, R. et al. (2021). Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. Circ Arrhythm Electrophysiol, 14(6), HAE0000000000000078. https://doi.org/10.1161/HAE.0000000000000078.
HAMID, A. K. et al. (2024). Empagliflozin and other SGLT2 inhibitors in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis. Ther Adv Cardiovasc Dis, 18, 17539447241289067. https://doi.org/10.1177/17539447241289067.
https://doi.org/10.1016/j.pharmthera.2022.108185.
JOGLAR, J. A. et al. (2024). 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 149(1), e1-e156. https://doi.org/10.1161/CIR.0000000000001193
LI, C.-X., Liang, S., Gao, L., & Liu, H. (2021). Cardiovascular outcomes associated with SGLT-2 inhibitors versus other glucose-lowering drugs in patients with type 2 diabetes: A real-world systematic review and meta-analysis. PLoS One, 16(2), e0244689. https://doi.org/10.1371/journal.pone.0244689
LI, H.-L. et al. (2021). Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis. Cardiovasc Diabetol, 20(1), 100. https://doi.org/10.1186/s12933-021-01293-8
LI, W.-J. et al. (2020). SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol, 19(1), 130. https://doi.org/10.1186/s12933-020-01105-5
MARIANI, M. V. et al. (2024). SGLT2i effect on atrial fibrillation: A network meta-analysis of randomized controlled trials. J Cardiovasc Electrophysiol, 35(9), 1754-1765. https://doi.org/10.1111/jce.16344
NEW YORK HEART ASSOCIATION. NYHA functional classification. Last updated in 2023.
ONG, H. T. et al. (2022). Effects of Sodium/Glucose Cotransporter Inhibitors on Atrial Fibrillation and Stroke: A Meta-Analysis. J Stroke Cerebrovasc Dis, 31(1), 106159. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106159
OUYANG, X. et al. (2023). Sodium-glucose cotransporter 2 inhibitor may not prevent atrial fibrillation in patients with heart failure: a systematic review. Cardiovasc Diabetol, 22(1), 124. https://doi.org/10.1186/s12933-023-01860-1
PANDEY, A. K. et al. (2021). Sodium-glucose co-transporter inhibitors and atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc, 10(17), e022222. https://doi.org/10.1161/JAHA.121.022222
SFAIROPOULOS, D. et al. (2023). Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials. Heart Fail Rev, 28(4), 925-936. https://doi.org/10.1007/s10741-022-10281-3
SHAH, Kevin S.; FANG, James C. Sodium-glucose cotransporter 2 inhibitors in heart failure. Annual Review of Pharmacology and Toxicology, 2022. DOI: https://doi.org/10.1146/annurev-pharmtox-052120-014725.
TSUTSUI, Hiroyuki. Recent advances in the pharmacological therapy of chronic heart failure:
WIVIOTT, Stephen D.; RAZ, Itamar; BONACA, Marc P.; MOSENZON, Ofri; KATO, Eri T.; CAHN, Avivit; SILVERMAN, Michael G.; ZELNIKER, Thomas A.; KUDER, Julia F.; MURPHY, Sabina A.; BHATT, Deepak L.; LEITER, Lawrence A.; McGUIRE, Darren K.; WILDING, John P. H.; RUFF, Christian T.; GAUSE-NILSSON, Ingrid A. M.; FREDRIKSSON, Martin; JOHANSSON, Peter A.; LANGKILDE, Anna-Maria; SABATINE, Marc S.; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine, v. 380, n. 4, p. 347-357, 24 jan. 2019. DOI: https://doi.org/10.1056/NEJMoa1812389.
ZHANG, X. et al. (2024). Effectiveness of sodium-glucose co-transporter 2 inhibitors on atrial fibrillation recurrence after catheter ablation: A systemic review and meta-analysis. Int J Cardiol, 413, 132359. https://doi.org/10.1016/j.ijcard.2024.132359
ZHENG, R.-J. et al. (2022). Association of SGLT2 Inhibitors With Risk of Atrial Fibrillation and Stroke in Patients With and Without Type 2 Diabetes: A Systemic Review and Meta-Analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol, 79(2), e145-e152. https://doi.org/10.1097/FJC.0000000000001183
ZHENG, S. et al. (2024). Effect of SGLT2 inhibitors on cardiovascular events in patients with atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials. Pacing Clin Electrophysiol, 47(1), 58-65. https://doi.org/10.1111/pace.14880.
